Abstract:The costs of developing the types of new drugs that have been pursued by traditional pharmaceutical firms have been estimated in a number of studies. However, similar analyses have not been published on the costs of developing the types of molecules on which biotech firms have focused. This study represents a first attempt to get a sense for the magnitude of the R&D costs associated with the discovery and development of new therapeutic biopharmaceuticals (specifically, recombinant proteins and monoclonal antibodies [mAbs]). We utilize drug‐specific data on cash outlays, development times, and success in obtaining regulatory marketing approval to estimate the average pre‐tax R&D resource cost for biopharmaceuticals up to the point of initial US marketing approval (in year 2005 dollars). We found average out‐of‐pocket (cash outlay) cost estimates per approved biopharmaceutical of $198 million, $361 million, and $559 million for the preclinical period, the clinical period, and in total, respectively. Including the time costs associated with biopharmaceutical R&D, we found average capitalized cost estimates per approved biopharmaceutical of $615 million, $626 million, and $1241 million for the preclinical period, the clinical period, and in total, respectively. Adjusting previously published estimates of R&D costs for traditional pharmaceutical firms by using past growth rates for pharmaceutical company costs to correspond to the more recent period to which our biopharmaceutical data apply, we found that total out‐of‐pocket cost per approved biopharmaceutical was somewhat lower than for the pharmaceutical company data ($559 million vs $672 million). However, estimated total capitalized cost per approved new molecule was nearly the same for biopharmaceuticals as for the adjusted pharmaceutical company data ($1241 million versus $1318 million). The results should be viewed with some caution for now given a limited number of biopharmaceutical molecules with data on cash outlays, different therapeutic class distributions for biopharmaceuticals and for pharmaceutical company drugs, and uncertainty about whether recent growth rates in pharmaceutical company costs are different from immediate past growth rates. Copyright © 2007 John Wiley & Sons, Ltd.

Recombinant Proteins for Industrial versus Pharmaceutical Purposes: A Review of Process and Pricing

Maximizing the Production of Recombinant Proteins in Plants: from Transcription to Protein Stability

Recombinant proteins production in Escherichia coli BL21 for vaccine applications: a cost estimation of potential industrial-scale production scenarios

RETRACTED ARTICLE: Strategies for efficient production of heterologous proteins in Escherichia coli

Switching from Recombinant to Ribosomal Delivery—A Humanitarian Cause

A Brief Reminder of Systems of Production and Chromatography-Based Recovery of Recombinant Protein Biopharmaceuticals

Optimization of Protein Expression in Mammalian Cells

Market Analysis and the R&D Trend for Recombinant Protein Therapeutics

Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D

High-throughput process development from gene cloning to protein production

Phase separation methods for protein purification: A meta‐analysis of purification performance and cost‐effectiveness

Strategies to maximize heterologous protein expression in Escherichia coli with minimal cost

The cost of biopharmaceutical R&D: is biotech different?

Optimising expression and extraction of recombinant proteins in plants

Sophisticated Cloning, Fermentation, and Purification Technologies for an Enhanced Therapeutic Protein Production: A Review

Improving Protein Quantity and Quality-The Next Level of Plant Molecular Farming

Metabolic costs of amino acid and protein production in Escherichia coli

Protein Production and Purification.

Mammalian cell culture for production of recombinant proteins: A review of the critical steps in their biomanufacturing

Recombinant pharmaceuticals from microbial cells: a 2015 update

Review of the Real and Sometimes Hidden Costs in Proteomics Experimental Workflows